Viewing Study NCT06467357

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:32 PM
Ignite Modification Date: 2026-01-22 @ 7:54 AM
Study NCT ID: NCT06467357
Status: RECRUITING
Last Update Posted: 2025-10-27
First Post: 2024-05-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Biliary Tract Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Biliary Tract Cancer View
None HER2 View
None HER2 expressing BTC View
None Trastuzumab deruxtecan View
None T-DXd View
None Rilvegostomig View